Novartis Targets Quick Launches For Zolgensma in Europe
Conditional Approval Finally Granted For SMA Gene Therapy
The Swiss major is offering a ‘Day One’ access program to governments and reimbursement agencies for Zolgensma, which is already available in France and will be shortly in Germany.
